Genesis Biopharma, Inc. (GNBP) Names Dr. Steven Rosenberg Inventor of Cancer Treatment Therapy to Scientific and Medical Advisory Board
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, announced today the appointment of Dr. Steven Rosenberg, Chief of the Surgery Branch at the National Cancer Institute, to their Scientific and Medical Advisory Board. Dr. Rosenberg pioneered the development of immunotherapy as a successful treatment for select patients with advanced cancer. Genesis Biopharma is currently working on the development and commercialization of treatments for various cancers, including a product known as Contego, which is a ready-to-infuse autologous cell therapy that uses tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma. Genesis Biopharma has licensed rights…